Vispo E - Search Results

1

Prevalence of natural polymorphisms at the HCV NS5A gene associated with resistance to daclatasvir, an NS5A inhibitor.

Plaza Z, Soriano V, Vispo E, del Mar Gonzalez M, Barreiro P, Seclén E, Poveda E. Plaza Z, et al. Among authors: vispo e. Antivir Ther. 2012;17(5):921-6. doi: 10.3851/IMP2091. Epub 2012 Mar 21. Antivir Ther. 2012. PMID: 22436385

2

Low response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C treated with abacavir.

Vispo E, Barreiro P, Pineda JA, Mira JA, Maida I, Martín-Carbonero L, Rodríguez-Nóvoa S, Santos I, López-Cortes LF, Merino D, Rivero A, Soriano V. Vispo E, et al. Antivir Ther. 2008;13(3):429-37. Antivir Ther. 2008. PMID: 18572756

3

Distinct hepatitis C virus kinetics in HIV-infected patients treated with ribavirin plus either pegylated interferon alpha2a or alpha2b.

Vispo E, Barreiro P, Rodriguez-Nóvoa S, Morello J, Labarga P, Martín-Carbonero L, Maida I, García-Gascó P, Soriano V. Vispo E, et al. Antivir Ther. 2008;13(4):511-7. Antivir Ther. 2008. PMID: 18672529 Clinical Trial.

4

Overestimation of liver fibrosis staging using transient elastography in patients with chronic hepatitis C and significant liver inflammation.

Vispo E, Barreiro P, Del Valle J, Maida I, de Ledinghen V, Quereda C, Moreno A, Macías J, Castera L, Pineda JA, Soriano V. Vispo E, et al. Antivir Ther. 2009;14(2):187-93. doi: 10.1177/135965350901400214. Antivir Ther. 2009. PMID: 19430093

5

Viral hepatitis and HIV co-infection.

Soriano V, Vispo E, Labarga P, Medrano J, Barreiro P. Soriano V, et al. Among authors: vispo e. Antiviral Res. 2010 Jan;85(1):303-15. doi: 10.1016/j.antiviral.2009.10.021. Epub 2009 Nov 1. Antiviral Res. 2010. PMID: 19887087 Review.

6

Incidence of liver cirrhosis in HIV-infected patients with chronic hepatitis B or C in the era of highly active antiretroviral therapy.

Tuma P, Medrano J, Resino S, Vispo E, Madejón A, Sánchez-Piedra C, Rivas P, Labarga P, Martín-Carbonero L, Barreiro P, Soriano V. Tuma P, et al. Among authors: vispo e. Antivir Ther. 2010;15(6):881-6. doi: 10.3851/IMP1630. Antivir Ther. 2010. PMID: 20834100

7

Predicted effect of direct acting antivirals in the current HIV-HCV-coinfected population in Spain.

Poveda E, Vispo E, Barreiro P, de Mendoza C, Labarga P, Fernández-Montero JV, Martin-Carbonero L, Soriano V. Poveda E, et al. Among authors: vispo e. Antivir Ther. 2012;17(3):571-5. doi: 10.3851/IMP1992. Epub 2011 Dec 15. Antivir Ther. 2012. PMID: 22293607

8

Different impact of IL28B polymorphisms on response to peginterferon-α plus ribavirin in HIV-positive patients infected with HCV subtypes 1a or 1b.

Vispo E, Rallon NI, Labarga P, Barreiro P, Benito JM, Soriano V. Vispo E, et al. J Clin Virol. 2012 Sep;55(1):58-61. doi: 10.1016/j.jcv.2012.05.012. Epub 2012 Jun 20. J Clin Virol. 2012. PMID: 22727259

9

Hepatitis C therapy: highlights from the 2012 annual meeting of the European Association for the Study of the Liver.

Barreiro P, Vispo E, Poveda E, Fernández-Montero JV, Soriano V. Barreiro P, et al. Among authors: vispo e. Clin Infect Dis. 2013 Feb;56(4):560-6. doi: 10.1093/cid/cis915. Epub 2012 Oct 22. Clin Infect Dis. 2013. PMID: 23090932

10

The changing face of hepatitis C in the new era of direct-acting antivirals.

Soriano V, Labarga P, Fernández-Montero JV, Benito JM, Poveda E, Rallon N, Sánchez C, Vispo E, Barreiro P. Soriano V, et al. Among authors: vispo e. Antiviral Res. 2013 Jan;97(1):36-40. doi: 10.1016/j.antiviral.2012.10.011. Epub 2012 Nov 9. Antiviral Res. 2013. PMID: 23147192

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

116 results

Search Page

Filters